Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bazedoxifene for Prevention of Postmenopausal Osteoporosis
NCT00481169Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2001
- Primary completion
- Jul 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bazedoxifene in osteoporosis (5 arms), sponsored by Pfizer. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at 24 months. Started Jul 2001; status: completed.
02
Drugs
bazedoxifene
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00481169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481169.